Page 1885 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 108 Graft-Versus-Host Disease and Graft-Versus-Leukemia Responses 1668.e9

graft-v-host disease: prognostic influence of prolonged thrombocytope- 390. Weiden PL, Flournoy N, Thomas ED, et al: Antileukemic effect of
nia after allogeneic marrow transplantation. Blood 72:546, 1988. graft-versus-host disease in human recipients of allogeneic-marrow
367. Sullivan KM, Witherspoon RP, Storb R, et al: Alternating-day cyclo- grafts. N Engl J Med 300:1068, 1979.
sporine and prednisone for treatment of high-risk chronic graft-v-host 391. Sullivan K, Weiden P, Storb R: Influence of acute and chronic
disease. Blood 72:555, 1988. graft-versus-host disease on relapse and survival after bone marrow
368. Koreth J, Matsuoka K, Kim HT, et al: Interleukin-2 and regulatory T transplantation from HLA-identical siblings as treatment of acute and
cells in graft-versus-host disease. N Engl J Med 365(22):2055–2066, chronic leukemia. Blood 73:1720, 1989.
2011. 392. Weiden PL, Flournoy N, Sanders JE, et al: Antileukemic effect of graft-
369. Anderson KC, Weinstein HJ: Transfusion-associated graft-versus-host versus-host disease contributes to improved survival after allogeneic
disease. N Engl J Med 323:315, 1990. marrow transplantation. Transplant Proc 13:248, 1981.
370. Orlin JB, Ellis MH: Transfusion-associated graft-versus-host disease. 393. Horowitz MM, Gale RP, Sondel PM, et al: Graft-versus-leukemia
Curr Opin Hematol 4:442, 1997. reactions after bone marrow transplantation. Blood 75:555, 1990.
371. Schroeder ML: Transfusion-associated graft-versus-host disease. Br J 394. Goldman JM, Gale RP, Horowitz MM, et al: Bone marrow transplanta-
Haematol 117:275, 2002. tion for chronic myelogenous leukemia in chronic phase. Increased risk
372. Bortin MM, Rimm AA, Saltzstein E: Graft-versus-leukemia: quantifica- for relapse associated with T-cell depletion. Ann Intern Med 108:806,
tion of adoptive immunotherapy in murine leukemia. Science 173:811, 1988.
1973. 395. Childs R, Chernoff A, Contentin N, et al: Regression of metastatic
373. Porter D, Connors J, Van Deerlin V, et al: Graft-versus-tumor induc- renal-cell carcinoma after nonmyeloablative allogeneic periphereal-
tion with donor leukocyte infusions as primary therapy for patients with blood stem-cell transplantation. N Engl J Med 343:750, 2000.
malignancies. J Clin Oncol 17:1234, 1999. 396. Martin PJ, Hansen JA, Storb R, et al: T cell depletion of donor marrow
374. van Rhee F, Lin F, Cullis JO, et al: Relapse of chronic myeloid leukemia for prevention of acute graft-versus-host disease. Haematol Blood Trans-
after allogeneic bone marrow transplant: the case for giving donor fus 29:42, 1985.
leukocyte transfusions before the onset of hematologic relapse. Blood 397. Mitsuyasu RT, Champlin RE, Gale RP, et al: Treatment of donor bone
83:3377, 1994. marrow with monoclonal anti-T-cell antibody and complement for
375. Kolb H-J, Schattenberg A, Goldman JM, et al: Graft-versus-leukemia the prevention of graft-versus-host disease. A prospective, randomized,
effect of donor lymphocyte transfusions in marrow grafted patients. double-blind trial. Ann Intern Med 105:20, 1986.
Blood 86:2041, 1995. 398. Soiffer RJ, Murray C, Mauch P, et al: Prevention of graft-versus-host
376. Kolb H, Mittermuller J, Clemm C, et al: Donor leukocyte transfusions disease by selective depletion of CD6-positive T lymphocytes from
for treatment of recurrent chronic myelogenousleukemia in marrow donor bone marrow. J Clin Oncol 10:1191, 1992.
transplant patients. Blood 76:2462, 1990. 399. Waldmann H, Polliak A, Hale G, et al: Elimination of graft-versus-
377. Porter D, Roth M, McGarigle C, et al: Induction of graft versus host host disease by in-vitro depletion of alloreactive lymphocytes with a
disease as immunotherapy for relapsed chronic myeloid leukemia. N monoclonal rat anti-human lymphocyte antibody (CAMPATH-1).
Engl J Med 330:100, 1994. Lancet 2:483, 1984.
378. Drobyski W, Keever C, Roth M, et al: Salvage immunotherapy using 400. Wagner JE, Santos GW, Noga SJ, et al: Bone marrow graft engineering
donor leukocyte transfusions as treatment for relapse chronic myelog- by counterflow centrifugal elutriation: results of a phase I-II clinical
enous leukemia after allogeneic bone marrow transplantation: efficacy trial. Blood 75:1370, 1990.
and toxicity of a defined T-cell dose. Blood 82:2310, 1993. 401. Young JW, Papadopoulos EB, Cunningham I, et al: T-cell-depleted
379. Hertenstein B, Wiesneth M, Novotny J, et al: Interferon-alpha and allogeneic bone marrow transplantation in adults with acute nonlym-
donor buffy coat transfusions for treatment of relapsed chronic myeloid phocytic leukemia in first remission. Blood 79:3380, 1992.
leukemia after allogeneic bone marrow transplantation. Transplantation 402. Apperley JF, Jones L, Hale G, et al: Bone marrow transplantation
56:1114, 1993. for patients with chronic myeloid leukaemia: T-cell depletion with
380. Weiden PL, Doney K, Storb R, et al: Antihuman thymocyte globulin Campath-1 reduces the incidence of graft-versus-host disease but may
for prophylaxis of graft-versus-host disease. A randomized trial in increase the risk of leukaemic relapse. Bone Marrow Transplant 1:53,
patients with leukemia treated with HLA-identical sibling marrow 1986.
grafts. Transplantation 27:227, 1979. 403. Goldman JM, Apperley JF, Jones L, et al: Bone marrow transplantation
381. Gale RP, Champlin RE: How does bone-marrow transplantation cure for patients with chronic myeloid leukemia. N Engl J Med 314:202,
leukaemia? Lancet 2:28, 1984. 1986.
382. Gale RP, Butturini A: [Stem cells, clonality and leukemia.]. Gematol 404. Slavin S, Morecki S, Weiss L, et al: Donor lymphocyte infusion: the
Transfuziol 39:3, 1994. use of alloreactive and tumor-reactive lymphocytes for immunotherapy
383. Horowitz MM, Bortin MM: Current status of allogeneic bone marrow of malignant and nonmalignant diseases in conjunction with alloge-
transplantation. Clin Transpl 41:1990. neic stem cell transplantation. J Hematother Stem Cell Res 11:265,
384. Gale R, Horowitz M, Ash R: Identical-twin bone marrow transplants 2002.
for leukemia. Ann Intern Med 120:646, 1994. 405. Farag SS, Fehniger TA, Becknell B, et al: New directions in natural
385. Porter DL, Antin JH: The graft-versus-leukemia effects of allogeneic killer cell-based immunotherapy of human cancer. Expert Opin Biol
cell therapy. Annu Rev Med 50:369, 1999. Ther 3:237, 2003.
386. Collins R, Rogers Z, Bennett M, et al: Hematologic relapse of chronic 406. Swann JB, Smyth MJ: Immune surveillance of tumors. J Clin Invest
myelogenous leukemia following allogeneic bone marrow transplanta- 117:1137, 2007.
tion: apparent graft-versus-leukemia effect following abrupt discontinu- 407. Reya T, Morrison SJ, Clarke MF, et al: Stem cells, cancer, and cancer
ation of immunosuppression. Bone Marrow Transplant 10:391, 1992. stem cells. Nature 414:105, 2001.
387. Higano C, Brixey M, Bryant E, et al: Durable complete remission 408. Yilmaz ÃH, Valdez R, Theisen BK, et al: Pten dependence distinguishes
of acute nonlymphocytic leukemia associated with discontinuation of haematopoietic stem cells from leukaemia-initiating cells. Nature
immunosuppression following relapse after allogeneic bone marrow 441:475, 2006.
transplantation: a case report of a probable graft-versus-leukemia effect. 409. Gilboa E: DC-based cancer vaccines. J Clin Invest 117:1195, 2007.
Transplantation 50:175, 1990. 410. Appelbaum FR: Haematopoietic cell transplantation as immunotherapy.
388. Sullivan K, Storb R, Buckner D, et al: Graft-versus-host disease as adop- Nature 411:385, 2001.
tive immunotherapy in patients with advanced hematologic neoplasms. 411. Farag SS, Bacigalupo A, Eapen M, et al: The effect of KIR ligand
N Engl J Med 320:828, 1989. incompatibility on the outcome of unrelated donor transplantation: a
389. Odom L, August C, Githens J: Remission of relapsed leukaemia during report from the center for international blood and marrow transplant
a graft-versus-host reaction. A “graft-versus-leukaemia” reaction in man? research, the European blood and marrow transplant registry, and the
Lancet 2:537, 1978. Dutch registry. Biol Blood Marrow Transplant 12:876, 2006.